During the Senseonics Holdings (NYSEAMERICAN:SENS) Q2 conference call on Aug. 9, CEO Tim Goodnow updated investors on the U.S. Food and Drug Administration approval process for its Eversense product. Eversense is designed to be a continuous glucose monitoring (CGM) device for diabetes patients. Once the FDA approval comes in for its 180-day version of Eversense,…